FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application for Myopic Choroidal Neovascularization
RF Energy Alliance Momentum and Growth Highlighted at EuMW 2016
FDA Grants Breakthrough Therapy Designation for Genentech’s Alecensa® (Alectinib) for First-Line Treatment of People with ALK-Positive NSCLC
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis
This iShares’ ETF has appeal, but investors don't have to go much further afield to find more-compelling options.
First movers, including Bristol-Myers, and firms that can aggregate a portfolio of immuno-oncology therapies will be positioned well.
These quality funds with smaller asset bases have portfolios built around solid companies.
Large drugmakers are out of favor, but some good funds are banking on a rebound.